Pembrolizumab + chemo (TNBC neoadjuvant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PEMBROLIZUMAB` `DRUG-PACLITAXEL` `DRUG-CARBOPLATIN` `DRUG-DOXORUBICIN` `DRUG-CYCLOPHOSPHAMIDE`

ID	`REG-PEMBRO-CHEMO-TNBC-NEOADJUVANT`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-BREAST-EARLY-2024` `SRC-NCCN-BREAST-2025`

Notes

KEYNOTE-522: pCR + EFS benefit in stage II-III TNBC (regardless of PD-L1 status). Continuation: 9 additional cycles of pembrolizumab adjuvant for total ~1 year of immunotherapy.

Used By

Indication

IND-BREAST-TNBC-EARLY-NEOADJUVANT - IND-BREAST-TNBC-EARLY-NEOADJUVANT

Regimen

REG-PEMBRO-CHEMO-TNBC-MET - Pembrolizumab + chemotherapy (TNBC, metastatic PD-L1+)